Developing a recombinant desmoglein 3-based antigen for serodiagnosis of pemphigus vulgaris (preliminary results)
Bulletin of Russian State Medical University · 27.10.2026 · (5)
DOI: 10.24075/brsmu.2026.065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin of Russian State Medical University, online erschienen am 27.10.2026. Verfasst von MV Shpilevaya und 4 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Pemphigus vulgaris is a severe autoimmune disorder resulting from production of anti-desmoglein 3 (Dsg3) antibodies. An accessible standardized antigenic component, the recombinant Dsg3 extracellular component, is necessary to develop domestic diagnostic ELISA kits. The retrospective experimental study aimed to produce a recombinant Dsg3 ectodomain (ЕС1-ЕС5 domain) in the heterologous expression system and assess its immunoreactivity with autoantibodies of patients having pemphigus vulgaris when used as a target antigen in ELISA. The synthetic gene encoding the Dsg3 ЕС1-ЕС5 domains was cloned into eukaryotic expression vectors p1.1-Tr2 and p1.2-GS. The resulting constructs were used for transfection of CHO-4BGD cells. The target protein was purified by affinity chromatography on the Ni-Sepharose FF sorbent. Immunoreactivity of the recombinant Dsg3 as an antigenic substrate was assessed by ELISA using sera from patients with pemphigus vulgaris (n = 12) and healthy donors (n = 5) under two buffer conditions: with EDTA (Dsg3-EDTA) and with added Ca2+ ions (Dsg3-Ca2+). The Euroimmun commercially available ELISA kit (target antigen: Dsg3 ectodomain) was used for reference. As a result, transient cultures of the cells producing the Dsg3 ЕС1-ЕС5 domains were obtained. The protein with the purity > 90% was isolated by affinity chromatography. When performing ELISA in the Dsg3-EDTA buffer, 33.3% of samples were classified as positive, while 50.0% were considered positive when using the Dsg3-Ca2+ buffer; the effect of adding Ca2+ was heterogeneous: 58.3% of samples showed the signal increase and 41.7% showed the decrease. The findings suggest the need to switch to the Dsg3 expression in human cells (HEK293).
Zitieren
APA
Shpilevaya, M., Arbuzova, N., Khodak, Y., Vorobiev, I., & Nosov, N. (2026). Developing a recombinant desmoglein 3-based antigen for serodiagnosis of pemphigus vulgaris (preliminary results). Bulletin of Russian State Medical University. https://doi.org/10.24075/brsmu.2026.065
Vancouver
Shpilevaya M, Arbuzova N, Khodak Y, Vorobiev I, Nosov N. Developing a recombinant desmoglein 3-based antigen for serodiagnosis of pemphigus vulgaris (preliminary results). Bulletin of Russian State Medical University. 2026. doi:10.24075/brsmu.2026.065
BibTeX
@article{Shpilevaya2026,
author = {Shpilevaya, MV and Arbuzova, NV and Khodak, YuA and Vorobiev, II and Nosov, NYu},
title = {Developing a recombinant desmoglein 3-based antigen for serodiagnosis of pemphigus vulgaris (preliminary results)},
journal = {Bulletin of Russian State Medical University},
year = {2026},
number = {5},
doi = {10.24075/brsmu.2026.065}
}
EUVIMED